南微醫學(688029.SH)：收到《無效宣告請求受理通知書》
格隆匯5月29日丨南微醫學(688029.SH)公佈，公司於2025年5月28日收到中華人民共和國國家知識產權局出具的《無效宣告請求受理通知書》。國家知識產權局對中科盛康提出的有關公司所持有的1項專利權無效宣告請求準予受理。
2022年9月，因中科盛康相關產品涉嫌侵害公司發明專利“一種止血夾”（專利號：201410222753.7），公司對中科盛康發起侵權訴訟，請求法院判令其立即停止製造及銷售並銷燬相關侵權產品，同時賠償公司經濟損失及合理維權支出，北京知識產權法院一審判決認定中科盛康構成侵權，判令其停止侵權行爲並賠償公司70萬元。中科盛康不服一審判決，上訴至最高人民法院。截至本公告披露日，案件尚在審理中。
專利權無效宣告是專利侵權訴訟中被控侵權人常用的抗辯手段。本次事項涉及的公司專利具有較好的穩定性，其技術方案在中國、歐盟、美國、日本、澳大利亞等國家地區均獲得發明專利授權。經會同有關知識產權服務專業機構及律師對中科盛康提交的證據分析論證，認爲公司具有取得有利審理結果的良好基礎。公司可旋轉重複開閉軟組織夾產品使用了涉案專利，其2024年國內銷售額約5.01億元，佔公司2024年營業收入約18.17%。公司相關止血夾產品已形成由國內外多項專利共同構建的專利保護體系，即使涉案專利最終被認定無效，該等產品仍然有其他專利進行保護。如涉案專利被最終認定無效，競爭對手可以無償、合法地使用其所涉及的技術方案，則公司前期對中科盛康發起的專利訴訟將無法獲得賠償。但專利無效不影響公司繼續使用該專利涉及的技術方案，不會影響公司繼續生產、銷售使用該專利的公司產品。並且公司已構建包括基礎技術、技術訣竅、專利等多層次核心技術體系，依靠產品更新迭代能力、成本優勢、規模效應以及營銷渠道優勢等核心競爭力而非僅依靠專利體系發揮競爭優勢，僅專利被認定無效並不影響公司核心技術體系及核心競爭力，不會對公司生產經營構成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
